To be realistic, if the price not go up by next week, nothing much to be expected as we r toward to year end, fund manager ramai cuti and market on holiday mode. So stay calm n hope for 1Q 2021 for kura2 to move on
Seriously nothing anyone post here whether vaccine or bamboo news will determine its share price. All determined/goreng by syndicate or shareholders and news of Sinopharm vaccine approval in Malaysia or QR profit generated by bamboo sales.
------------------------------ Kanger potential revenue streams aside from distribution of Covid-19 vaccine and medical equipments from Sinopharm Group are as follows :
1) Manufacture and trading of bamboo flooring and related products : Kanger International poised to be world’s largest producer of bamboo products
2) The Group (Kanger Group) being the sole exclusive distributor in the China for "Classen", a brand of a high-end wood flooring products originated from Germany, and will continue to focus its efforts to promote and sell Classen's products.
With rising acceptance of the Classen brand in China, Kanger was recently presented with the Excellence Award for Best Supplier to the Chinese Bed & Breakfast Industry at the 2019 International B&B Industry Development Forum and the 2019-2020 Illustrious Brand award by the China Renovation & Construction Alliance.
Sales of Classen products have been encouraging and proved to be a good complement to the group, generating revenue to the group whilst the group scaled down its production of in-house bamboo products to make way for the relocation exercise of the bamboo plant.
3) Kanger International Bhd has completed the development of AutoCity and Kyriad Hotel in China worth RM500 million collectively. In March, Kanger had secured 10-year lease agreements for AutoCity and Kyriad Hotel.
6) Kanger invests RM77mil on glove factory (Not sure what is the latest status of this glove factory) The group will invest RM77 million to set up the plant in Ijok, Selangor, and produce at least one billion pieces of gloves per annum.
Wu has said the group is targeting to start full production in the first quarter of 2021 as there are pipeline orders in the Middle East.
It was reported that Kanger will invest RM77 million to set up a glove manufacturing plant in Ijok, Selangor next year. It will acquire five acres in Ijok for RM6.8 million through its wholly owned unit Kanger Glove Manufacturing Sdn Bhd. Kanger Glove will spend about RM70 million to build the plant and install 8 production lines to produce medical, surgical and/or nitrile gloves for the Middle East region.
The 8 production lines are expected to produce at least one billion pieces of gloves per annum. In a filing with Bursa Malaysia in August, Kanger had said that a substantial proportion of the total output of the production will be sold to Dubai-based Constellation Holdings Ltd (CHL).
Note: This is a shelf company without any paid up capital. It is also not registered for commencement of business. The above info is obtained from SSM Company Search.
The news posted are actually good... for guidance whether to invest and hold for future price appreciation or short term trading or cut loss if no faith in bamboo or vaccine biz
MadCow75@Mr Dumb.MOU LA LOI LOA also you cannot differentiate,better dont talk shit.
MOU is not confirm agreement.Anytime can be call off.
Question,what happen Kanger MOU JV glove factory.Any update news?No right.Have you read the detail MOU agreement,1 clause state in 3 months time.Now already over 3 months.Means what?Have they put in detail in their quarter report about healthcare sector new venture (either glove or vaccine)?
At least a few person have cut loss early after i posted my comments.What is your contribution,no at all.Just influence people to buy based on news.
Congratulation to reader who did not buy because of news.Guys,remember this..in investing,there are only 2 factors which trigger buying momentum.FA and TA.The rest you can call rubbish.
Will visit here again if only Kanger confirm the uptrend,as for now break 21.5 cents with strong volume.
Now,downtrend mode is affirmative.16.5 cents is a fake q.Who did not cut loss,may put extra cautious.Once 16.5 break,cut loss at least half and wait at another support level 12.5.
Dont read too much on rubbish news.Good luck and happy trading!!!
Bursa Malaysia expected to break 1,700 psychological level
Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.
1) Firstly, it is standard procedure to halt a clinical trial when ANY serious negative event has been reported in the clinical trials regardless of whether there is any causal realtionship. This is to allow regulators to investigated analyse the cause of the event to determine whether there is a strong causal link between the vaccine and the negative event. Case in point, Sinovac vaccine trial was quite recently halted due to death of a volunteer when the volunteer death has got nothing to do with the vaccine. The volunteer COMMITTED SUICIDE. Needless to say, the trial was allowed to resume after the investigation.
2) As regulators we are fully aware about all these reported side effects of Covid vaccines. However, one must take into account the expected background rate or frequency of the event in the general population in order to conclude whether there is causal relationship or not. This was why FDA proceeded to grant authorization to Pfizer vaccine just yesterday despite reports of Bell's palsy in 4 volunteers who were vaccinated simply because "The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no clear basis upon which to conclude a causal relationship". See information below for further information.
3) Likewise, in this case ONLY 1 volunteer was reported to have Guillain-Barre syndrome. So it is too early to conclude anything until further investigations.
---------------------
Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020 FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine
Among non-serious unsolicited adverse events, there was a numerical imbalance of four cases of Bell’s palsy in the vaccine group compared with no cases in the placebo group, though the four cases in the vaccine group do not represent a frequency above that expected in the general population.
Bell’s palsy was reported by four vaccine participants and none in the placebo group. These cases occurred at 3, 9, 37, and 48 days after vaccination. One case (onset at 3 days postvaccination) was reported as resolved with sequelae within three days after onset, and the other three were reported as continuing or resolving as of the November 14, 2020 data cut-off with ongoing durations of 10, 15, and 21 days, respectively. The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no clear basis upon which to conclude a causal relationship at this time, but FDA will recommend surveillance for cases of Bell’s palsy with deployment of the vaccine into larger populations.
Bell’s palsy was reported by four vaccine participants. From Dose 1 through 1 month after Dose 2, there were three reports of Bell’s palsy in the vaccine group and none in the placebo group. This observed frequency of reported Bell’s palsy is consistent with the expected background rate in the general population. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to BNT162b2 vaccine.
From Dose 1 through 1 month after Dose 2, there were three reports of Bell’s palsy in the vaccine group and none in the placebo group. This observed frequency of reported Bell’s palsy is consistent with the expected background rate in the general population. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to BNT162b2 vaccine.
This observed frequency of reported Bell’s palsy is consistent with the expected background rate in the general population. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to BNT162b2 vaccine.
Although the safety database revealed an imbalance of cases of Bell’s palsy (4 in the vaccine group and none in the placebo group), causal relationship is less certain because the number of cases was small and not more frequent than expected in the general population. Further signal detection efforts for these adverse events will be informative with more widespread use of the vaccine.
Exactly, but they allowed the trial to proceed after further investigations as western regulators concluded that there is no strong causal relationship between the negative event and the vaccine...
Also take into account that sinopharm vaccine has been used in more than 1 million people without serious side effects . Hence , based on that fact , the frequency of serious side effects of sinopharm is still much much much lower than western vaccines such as Pfizer , Moderna and AstraZeneca vaccine considering the number of subjects that have been vaccinated with western vaccines...
@noobie123 don’t forget even Johnson and Johnson vaccine trial was halted due to serious side effects but eventually allowed to proceed after further investigations by regulators concluded that there was no strong causal relationship between the vaccine and the serious side effect
He is also the Vice President of Persatuan Muafakat One Belt One Road.
PMOBOR will provide advice and network links for Malaysian industries, its neighboring countries and Eurasia to identifying, establishing business opportunities with Chinese enterprises through the One Belt One Road Initiatives
Persatuan Muafakat One Belt One Road (One Belt One Road Association), is a non profit organization. The Association consists of a group of Malaysian entrepreneurs who have investment in China. Through our strong presence and business network, we have been actively promoting Malaysia as a prime investment destination in South East Asia for Chinese entrepreneurs. The essence of the Association‘s platform is to promote regional and cross-continental connectivity between Malaysia China, South East Asia and Eurasia. The platform will enable Malaysia and China industry leaders with network support business opportunities available through the One Belt One Road (OBOR) strategies and initiatives.
Vice President - Prof Datuk Seri Dr Md Zabid Abdul Rashid, President of UNIRAZAK
Wu Wai Kong Leng Xingmin Liu Zhenyu Lim Lai Choy @ Lim Aun Nee Setiakon Builders Sdn Bhd8 Tan Lik Houe Hongkong Huanshiqiu Finance Investment Limited Nie Hui Li Chunming Hongkong Jiutian Asset Management Limited Syed Sirajuddin Putra Jamalullail Dahua Holding (HK) Co Limited Alliancegroup Nominees (Tempatan) Sdn Bhd Syed Razlan Ibni Syed Putra Ng Kim Keong Wong Wai Lum Huam Hong Ping Chen Shenghuai Doh Tee Leong Lim Kam Seng Advance Opportunities Fund Phillip Securities (Hong Kong) LTD Tan Wye Chuan Phua Wee Seng Tan Lee Kock Ho Kee Lian Ng Hui Kheng Lim Keh Yoong Phua Lam Huat
Sanofi suffers major setback in development of a Covid-19 vaccine
One of the world’s leading vaccine manufacturers has suffered a major setback in its work to produce a Covid-19 vaccine. The problem will push the timeline for deployment of Sanofi Pasteur’s vaccine — if it is approved — from the first half of 2021 into the second half of the year, the company said Friday.
The news is not just disappointing for Sanofi and its development partner, GlaxoSmithKline, which is providing an adjuvant used in the vaccine. The companies have contracts with multiple countries, including the United States and Britain, as well as the European Union.
Just my thoughts regarding one of the plausible causes of Guillain-Barre syndrome reported in that ONE volunteer in the Peru clinical trial of Sinopharm Vaccine.
It is possible that the particular volunteer contracted Covid-19 infection which led to Guillain-Barre syndrome as a complication.
-----------------
Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports
Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the coronavirus disease 2019 (COVID-19) has neurological symptoms. COVID-19 patients have such clinical symptoms as headache, vomiting, nausea, dizziness, myalgia, anosmia, ageusia, and disorder of consciousness. These symptoms confirm that the nervous system is involved in the COVID-19 infection. Guillain-Barré syndrome (GBS) is a heterogeneous disorder which often follows a viral infection. According to the assessment case reports from the beginning of the COVID-19 infection so far, it is possible that GBS is linked to the COVID-19 infection. It seems that paying attention to the neurological effects of COVID-19 is necessary.
According to the case reports from around the world, it is possible that GBS is linked to the COVID-19 infection. However, more cases with epidemiological data should be studied and future investigations should be carried out in this regard. Due to the possible association of GBS and COVID-19, it is recommended that the patients be followed up by physicians with respect to neurological manifestations. Finally, it is suggested that research on the relationship between COVID-19 and the nervous system be not limited to the current period so that if we encounter a new type of this virus in the future, the necessary measures could be taken.
COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports
Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19.
GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.
Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.
Rileks... Honestly at this point, i am not bothered what Anwar says. The last time he went to Agong, nothing extraordinary happened. Subsequently, during the parliamentary debate on budget, there was no bloc vote as he didnt have the majority to support...So i am quite doubtful....
PETALING JAYA: A pro-Anwar Ibrahim group has asked the PKR president to “burn” the statutory declarations (SDs) of support for him, move on and focus on the next general election (GE15).
Otai Reformis secretary Abdul Razak Ismail said this was because the opposition failed to garner enough support to oppose the budget allocations for 22 ministries in the Dewan Rakyat.
He added that Pakatan Harapan (PH) should give up hope of wresting Putrajaya from the Perikatan Nasional-led government through the support of MPs.
“When PH failed to get 15 MPs to support a request for a bloc vote on the federal budget at the policy stage, the perception was that the game was already over.
Wah Nur Jazlan Mohamed still so powerful speaking on behalf of UMNO. So conclusion is UMNO may decide to cooperate with PKR (Anwar) and DAP ?
-----------------
Umno may ditch PN, work with PH if PPBM’s ‘antics’ continue, says Nur Jazlan
Umno will not hesitate to ditch Perikatan Nasional (PN) and go it alone in the next general election (GE15) or even tie-up with Pakatan Harapan (PH) if PPBM continues to punch above its weight to dominate the coalition, a senior Umno leader said today.
Johor Umno deputy chief Nur Jazlan Mohamed warned the party stood to pay a heavy price if it stayed in the ruling coalition and allowed a “weak” PPBM to take the lead at the polls.
Nur Jazlan said there was “simmering frustration” among Umno members against PPBM’s attempts to impose itself as a dominant force in the PN government.
He said, looking at the situation at hand, the party’s grassroots should start thinking “broadly to understand” why the party should explore options such as cooperating with PH component parties, including DAP.
Umno man tells of efforts to undo 'No Anwar, No DAP' policy
Umno's Ketereh MP Annuar Musa said there are efforts to undo the position the party has taken not to cooperate with PKR president Anwar Ibrahim and DAP.
Meanwhile, Johor Umno deputy chief Nur Jazlan Mahmed warned that Umno might ditch Perikatan Nasional and work with Harapan if Bersatu continued to make Umno play second fiddle.
"Logic dictates that the strongest party in a coalition (must) be the dominant party, whether it's via an election or deciding on the posts of prime minister, menteri besar or chief minister. We need a reset at the federal and state levels," he was quoted as saying by Free Malaysia Today.
He added the party's grassroots should explore cooperation with Harapan, including DAP.
Even though there is much animosity between Umno and DAP but electorally, DAP does not contest in most of Umno's seats as both parties serve very different demography.
In contrast, Umno has vast overlaps with Bersatu and PAS in terms of the constituencies that they want to contest as all three focus on the Malay and Muslim community.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
18KHarmoni
803 posts
Posted by 18KHarmoni > 2020-12-12 15:52 | Report Abuse
To be realistic, if the price not go up by next week, nothing much to be expected as we r toward to year end, fund manager ramai cuti and market on holiday mode. So stay calm n hope for 1Q 2021 for kura2 to move on